Phaseline

Targets › SELP

SELP (P-selectin): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 3, 1 Phase 4, 1 Phase 2; Hematology, Oncology; next expected readout Jul 2029.

Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. (UniProt, P16109)

Open in Phaseline: the race on SELP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisCrizanlizumab (SEG101)
P-selectin blocker
SELPPhase 4Sickle Cell Disease; Sickle Cell Disease (SCD); Advanced GlioblastomaJul 2029

Conditions

Sickle Cell Disease (2) Sickle Cell Disease (SCD) (1) Advanced Glioblastoma (1)

Modalities

antibody (1)

Companies

Novartis (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.